According to several reported studies, serum levels of vitamin D are decreased in patients aff ected by kidney diseases, as compared with the general population, in diff erent stages of renal-function loss. 4 However, these studies, although they document kidney disease and renal function well, are restricted to a small number of patients. At variance, the article by Chonchol and Scragg 5 (this issue) provides some interesting data based on population data. To overcome the limitations of studies in small groups of patients, Chonchol and Scragg collected data from the Th ird National Health and Nutrition Examination Survey (NHANES III). Th e authors clearly demonstrate, by appropriate statistical analysis, that serum levels of 25-hydroxyvitamin D, a measure of blood stores of vitamin D, are eff ectively reduced in uremic patients, but only when renal function is severely lost (glomerular fi ltration rate ranging from 15 to 29 ml/min/ 1.73 m 2 ) as compared with that of subjects with normal renal function, whereas in patients aff ected by only mild or moderate loss of renal function the serum level of 25-hydroxyvitamin D is normal. In addition, the results of the statistical analysis showed that 25-hydroxyvitamin D levels and loss of renal function have indepen dent inverse associations with insulin resistance, 5 suggesting that the relation between vitamin D and insulin resistance, if any, still has to be elucidated in more detail. Th us, the results of this study make some important contributions to the understanding of the pathophysiological role of vitamin D in progressive renal diseases and its possible implication for pharmacological therapy. In addition, they should guide future investigations of the potential role of vitamin D supplementation.
Th e theoretical possibility that vitamin D is involved in the pathophysiology of progressive renal disease is based on the fact that, besides secondary hyperparathyroidism, this molecule is involved in other cellular and metabolic functions known to be altered in renal diseases. One mechanism that has been better commentar y characterized in the progression of renal disease is the activation of the renin-angiotensin system. Relevant experimental and clinical observations demonstrate that the antagonism of the biological action of angiotensin II prevents or ameliorates renal structural and functional changes. 6 Th e observation that vitamin D acts as a negative endocrine regulator for the renin-angiotensin system 7 would indicate a potential involvement of vitamin D in the progressive loss of renal function. Another possible mechanism that could relate vitamin D and progression of renal disease is the involvement of vitamin D in cell cycle regulation and cell diff erentiation. 3 It is of interest that vitamin D supplementation decreased podocyte loss and hypertrophy in the classical model of experimental renal disease progression, the surgical reduction of renal mass in the rat. 8 Th ere is also experimental evidence that vitamin D is related to insulin resistance, 9 a condition frequently observed in patients aff ected by progressive renal disease. Finally, vitamin D is known to modulate the functioning of immune cells such as T lymphocytes and monocytes, 10 which are frequently involved in the immunological reactions associated with renal disease progression.
On the basis of this body of evidence and of these theoretical considerations, it has been suggested that vitamin D has a potential role in kidney disease progression and that consequently vitamin D supplementation should be adopted to prevent renal disease and cardiovascular events in these patients. Th e Kidney Disease Outcomes Quality Initiative guidelines also recommend measurements of 25-hydroxyvitamin D serum levels in patients with advanced chronic renal disease. However, the data provided by Chonchol and Scragg 5 clearly indicate that serum levels of 25-hydroxyvitamin D are not signifi cantly reduced in patients aff ected by renal disease unless the glomerular fi ltration rate is lower than 29 ml/min/1.73 m 2 , suggesting a condition not characterized by vitamin D deficiency until the disease is in the advanced stage. Th ese data pose two challenges. Th e fi rst is to identify the role of vitamin D in the pathophysiological mechanisms responsible for these diseases, especially in the initiation and the first stage of progression. Th e second is related to the potential eff ects of vitamin D supplementation therapy in these patients. On the basis of the data reported by Chonchol and Scragg, 5 both these issues need to be further elucidated.
In addition, clinical data demonstrate benefi cial eff ects of vitamin D supplementation in these patients, even in the early phase of the disease. 4 How this relates to the previously mentioned normal level of vitamin D should be studied in more detail. On the basis of this consideration, vitamin D supplementation in these patients should be carefully evaluated in order to gain more evidence on the eff ective target of these therapies and the potential results that could be obtained in slowing the rate of renal disease progression. On the other hand, the data of Chonchol and Scragg 5 do confi rm that vitamin D is defi cient in uremic patients in the advanced stage of the disease. Th ese results are important for the understanding of the cardiovascular events that frequently affect patients with end-stage renal disease. At the moment, deeper knowledge of the relative importance of the previously mentioned biological systems, linked to vitamin D, for the cardiovascular morbidity and mortality in these patients is needed. Hopefully, the large-population data provided by Chonchol and Scragg 5 will stimulate experimental and clinical studies with the aim to investigate the eff ective role of vitamin D in the early phase of the disease, when serum levels of the vitamin D cascade are not signifi cantly aff ected, as well as in the late phase that is characterized by vitamin D defi ciency.
Finally, the results of Chonchol and Scragg 5 also indicate that renal dysfunction and vitamin D have independent inverse associations with insulin resistance, while in the general population there is evidence of close association between insulin sensitivity and serum levels of 25-hydroxyvitamin D. Thus, more complex mechanisms may relate these pathological manifestations, and more focused experimental and clinical research may help to elucidate them in the near future with the aim of avoiding unrealistic expectations for therapeutic approaches that have potential use in a large patient population. One of the most important predictive factors of survival on dialysis is the presence of malnutrition. 1, 2 Previous studies have demonstrated that a signifi cant proportion of hemodialysis patients and chronic ambulatory peritoneal dialysis patients are malnourished. Th ese patients have increased morbidity and mortality and a poorer quality of life as compared with patients who are adequately nourished. Impaired nutrition may be measured by a variety of methods, but those methods that measure body composition directly (total-body nitrogen analysis and dualenergy X-ray absorptiometry) demonstrate that lean body mass is reduced in patients with renal impairment. 3, 4 Th ese changes are demonstrable at the initiation of dialysis and are likely to develop in patients with mild to moderate chronic kidney disease (CKD). Negative nitrogen balance and sarcopenia can result from decreased protein anabolism or increased protein catabolism or both. Th e balance between these factors and relative contributions of other conditions that cause sarcopenia are still to be defi ned. Decreased protein anabolism may result from disuse of muscles, suboptimal protein intake, intercurrent illness, and medications, whereas increased protein catabolism can result from acidosis, microinfl ammatory processes related to increased cytokines, oxidative stress, and the reduced actions of anabolic hormones such as insulin. Th e increased mortality and morbidity observed in dialysis patients with malnutrition or depleted muscle mass are principally due to an increase in cardiovascular events. 5 In view of this, it is important not only to understand the mechanisms by which sarcopenia may occur, but also to understand the association between altered body composition and clinical outcomes in CKD. Recent literature has highlighted the eff ects of chronic infl ammation and oxidative stress in predisposing CKD patients to malnutrition and increased vascular disease. 6 Chronic infl ammation may predispose to impaired nutritional status by enhancing protein catabolism. Associations between chronic infl ammation, measured as elevated C-reactive protein or proinfl ammatory cytokines, impaired nutritional status, and subclinical and clinically overt vascular disease, have been documented in patients at the commencement of dialysis. Furthermore, systemic infl ammation may result in reductions in total cholesterol levels, which may account for the altered epidemiological association of an inverse relationship between total cholesterol levels and mortality reported by some investigators in dialysis patients.
Although the malnutrition, inflammation, atherosclerosis hypothesis may explain many of the clinical associations of malnutrition in dialysis patients, 6 CKD is associated with complex metabolic changes, and Siew et al. 7 (this issue) now highlight the importance of another metabolic eff ect of CKD -insulin resistance. It is well documented that insulin resistance is a feature of advanced CKD, and there is some evidence that insulin resistance occurs in mild to moderate CKD. Th e cause of insulin resistance in nondiabetic CKD is not apparent, but it may be related to central adiposity, the microinfl ammatory environment, or other metabolic defects. Insulin resistance has been shown to be an independent predictor of survival in dialysis patients. 8 It has been hypothesized that insulin resistance may increase vascular risk in dialysis patients in the same way observed in the general population, because of the tendency of vascular risk factors to cluster in subjects who are insulin resistant.
